Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc ICOTF


Primary Symbol: T.MSCL Alternate Symbol(s):  MSCLF

Healthcare Biotechnology
Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).


TSX:MSCL - Post by User

Satellos Bioscience Inc > Listed and Shown as $2.10
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(285)
•••
Comment by beenthereon Aug 18, 2021 8:18pm
134 Views
Post# 33728170

RE:RE:RE:RE:RE:RE:Listed and Shown as $2.10

RE:RE:RE:RE:RE:RE:Listed and Shown as $2.10I have been with TD for 15 years and believe  me more than once I have given it lots of thought but.

Have you ever changed brokers? I have 3 times!
Depending on what types of investments you have in your account it is no fun.
Could take months to do! That's why I stay with them (TD) now

I don't see how you could do anything anyway.
My account shows the same ICO shares as always.
Just for the fun of it I tried to sell and it would not let me.
Said (ICO) was not a viable stock.
Tried MSCL and said I didn't have the stock.

So I (we) are stuck until TD get their act in great!

What do you expect from TD?

Maybe you never noticed but when you log on early in the morning your account doesn't fully show your account correctly until later in the morning! Pathetic!

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities